Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28002484 | 0.88 | HSP90AB1 (0.54) | HSP90AB1ALOX5CA1CA2LMNA | |
| SCHEMBL1525224 | 0.88 | HSP90AB1 (0.54) | HSP90AB1ALOX5GAAALDH1A1GFER | |
| SCHEMBL11215998 | 0.88 | ALDH1A1 (0.58) | HSP90AB1ALOX5GAAALDH1A1GFER | |
| SCHEMBL14666331 | 0.87 | HSP90AB1 (0.53) | HSP90AB1ALOX5LMNAGAAALDH1A1 | |
| SCHEMBL7131019 | 0.85 | KMT2A (0.58) | HSP90AB1LMNAGAAALDH1A1TDP1 | |
| SCHEMBL28708164 | 0.84 | ALOX5 (0.56) | ALOX5CA12CA1CA2CA3 | |
| SCHEMBL2913406 | 0.82 | LMNA (0.57) | ALOX5CA12CA1CA2CA3 | |
| SCHEMBL1278855 | 0.82 | GAA (0.66) | ALOX5CA12CA1CA2CA3 | |
| SCHEMBL490925 | 0.81 | ALOX5 (0.62) | ALOX5CA12CA1CA2CA3 | |
| SCHEMBL5690995 | 0.81 | HSP90AB1 (0.54) | HSP90AB1ALOX5GAAALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1740225-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1740225-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105159-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | CITIZENS BANK, N.A. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085891-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | HSP90AB1 2294/4885ALOX5 38/4885CA12 1744/4885 |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | HSP90AB1 1297/4885ALOX5 2982/4885CA12 1070/4885 |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | HSP90AB1 1297/4885ALOX5 2982/4885CA12 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.